Top

Published in:

01-03-2018 | Research Paper

ETS1 regulates Twist1 transcription in a Kras^G12D/Lkb1^−/− metastatic lung tumor model of non-small cell lung cancer

Authors: Guetchyn Millien, Yuxia Cao, Carl J. O’Hara, Jean-Bosco Tagne, Anne Hinds, Mary C. Williams, Maria I. Ramirez, Hasmeena Kathuria

Published in: Clinical & Experimental Metastasis | Issue 3/2018

Abstract

Distinct members of the Ets family of transcription factors act as positive or negative regulators of genes involved in cellular proliferation, development, and tumorigenesis. In human lung cancer, increased ETS1 expression is associated with poor prognosis and metastasis. We tested whether ETS1 contributes to lung tumorigenesis by binding to Twist1, a gene involved in tumor cell motility and dissemination. We used a mouse lung cancer model with metastasis driven by conditionally activated Kras and concurrent tumor suppressor Lkb1 loss (Kras^G12D/ Lkb1^−/− model) and a similar model of lung cancer that does not metastasize, driven by conditionally activated Kras alone (Kras^G12D model). We show that Ets1 and Twist1 gene expression differs between Kras^G12D tumors (low Ets1 and Twist1 expression) and Kras^G12D/Lkb1^−/− tumors (high Ets1 and Twist1 expression). In human lung tumors, ETS1 and TWIST1 expression positively correlates and low combined ETS1 and TWIST1 levels are associated with improved survival compared to high levels. Using mouse cell lines derived from Kras^G12D and Kras^G12D/Lkb1^−/− mouse models and the human lung cancer (A549) cell line, we show that ETS1 regulates Twist1 expression. Chromatin immunoprecipitation assays confirm binding of ETS1 to the Twist1 promoter. Overexpression studies show that ETS1 transactivates Twist1 promoter activity in mouse and human cells. Silencing endogenous Ets1 by siRNA in mouse cell lines decreases Twist1 mRNA levels, decreases invasion, and increases cell growth. Ets1 and Twist1 are at the crossroad of several signaling pathways in cancer. Understanding their regulation may inform the development of therapies to impair lung tumor metastasis.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013S0092-8674(11)00127-9 CrossRefPubMed

Dutt A, Wong KK (2006) Mouse models of lung cancer. Clin Cancer Res 12(14 Pt 2):4396s-4402s. https://doi.org/10.1158/1078-0432.CCR-06-0414 CrossRef

Gazdar AF, Hirsch FR, Minna JD (2016) From mice to men and back: an assessment of preclinical model systems for the study of lung cancers. J Thorac Oncol 11 (3):287–299.https://doi.org/10.1016/j.jtho.2015.10.009S1556-0864(15)00031-3 CrossRefPubMed

Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, Garcia-Echeverria C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17(6):547–559. https://doi.org/10.1016/j.ccr.2010.04.026S1535-6108(10)00199-6 CrossRefPubMedPubMedCentral

Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807–810CrossRefPubMed

Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075. https://doi.org/10.1038/nature07423nature07423 CrossRefPubMedPubMedCentral

Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansen S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Janne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6):1107–1120. https://doi.org/10.1016/j.cell.2012.08.029S0092-8674(12)01061-6 CrossRefPubMedPubMedCentral

Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG, Sidransky D (2002) Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62(13):3659–3662PubMed

Yamaguchi E, Nakayama T, Nanashima A, Matsumoto K, Yasutake T, Sekine I, Nagayasu T (2007) Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma. Tohoku J Exp Med 213(1):41–50CrossRefPubMed

10.

Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y (2001) Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res 101(2):242–247. https://doi.org/10.1006/jsre.2001.6279S0022-4804(01)96279-1 CrossRefPubMed

11.

Seth A, Watson DK (2005) ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41(16):2462–2478. https://doi.org/10.1016/j.ejca.2005.08.013 CrossRefPubMed

12.

Hollenhorst PC, Jones DA, Graves BJ (2004) Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 32(18):5693–5702. https://doi.org/10.1093/nar/gkh906 CrossRefPubMedPubMedCentral

13.

Sharrocks AD (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2(11):827–837. https://doi.org/10.1038/3509907635099076 CrossRefPubMed

14.

Yang J, Mani SA, Weinberg RA (2006) Exploring a new twist on tumor metastasis. Cancer Res 66(9):4549–4552. https://doi.org/10.1158/0008-5472.CAN-05-3850 CrossRefPubMed

15.

Howe LR, Watanabe O, Leonard J, Brown AM (2003) Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 63(8):1906–1913PubMed

16.

Qin L, Liu Z, Chen H, Xu J (2009) The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 69(9):3819–3827. https://doi.org/10.1158/0008-5472.CAN-08-43890008-5472.CAN-08-4389 CrossRefPubMedPubMedCentral

17.

Kaufmann O, Dietel M (2000) Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 36(1):8–16CrossRefPubMed

18.

Ge S, Crooks GM, McNamara G, Wang X (2006) Fluorescent immunohistochemistry and in situ hybridization analysis of mouse pancreas using low-power antigen-retrieval technique. J Histochem Cytochem 54(7):843–847. https://doi.org/10.1369/jhc.5B6902.2006 CrossRefPubMed

19.

Namimatsu S, Ghazizadeh M, Sugisaki Y (2005) Reversing the effects of formalin fixation with citraconic anhydride and heat: a universal antigen retrieval method. J Histochem Cytochem 53(1):3–11. https://doi.org/10.1369/jhc.4C6466.2005 CrossRefPubMed

20.

Gilbert-Ross M, Konen J, Koo J, Shupe J, Robinson BS, Wiles WGT, Huang C, Martin WD, Behera M, Smith GH, Hill CE, Rossi MR, Sica GL, Rupji M, Chen Z, Kowalski J, Kasinski AL, Ramalingam SS, Fu H, Khuri FR, Zhou W, Marcus AI (2017) Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI Insight 2(5):e90487. https://doi.org/10.1172/jci.insight.9048790487 CrossRefPubMedPubMedCentral

21.

Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK (2013) Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 3(8):870–879. https://doi.org/10.1158/2159-8290.CD-13-00152159-8290.CD-13-0015 CrossRefPubMedPubMedCentral

22.

Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X (2013) Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS ONE 8(4):e62171. https://doi.org/10.1371/journal.pone.0062171PONE-D-12-36804 CrossRefPubMedPubMedCentral

23.

Ko JH, Miyoshi E, Noda K, Ekuni A, Kang R, Ikeda Y, Taniguchi N (1999) Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines. J Biol Chem 274(33):22941–22948CrossRefPubMed

24.

Nakashima H, Hashimoto N, Aoyama D, Kohnoh T, Sakamoto K, Kusunose M, Imaizumi K, Takeyama Y, Sato M, Kawabe T, Hasegawa Y (2012) Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells. Mol Carcinog 51(5):400–410. https://doi.org/10.1002/mc.20802 CrossRefPubMed

25.

Kathuria H, Cao Y, Hinds A, Ramirez MI, Williams MC (2007) ERM is expressed by alveolar epithelial cells in adult mouse lung and regulates caveolin-1 transcription in mouse lung epithelial cell lines. J Cell Biochem 102(1):13–27. https://doi.org/10.1002/jcb.21270 CrossRefPubMed

26.

Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ, Wang LH (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283(21):14665–14673. https://doi.org/10.1074/jbc.M707429200M707429200 CrossRefPubMedPubMedCentral

27.

Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G, Artyomov MN, Schreiber R, Govindan R, Meyerson M (2016) Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 48(6):607–616. https://doi.org/10.1038/ng.3564ng.3564 CrossRefPubMedPubMedCentral

28.

Goswami CP, Nakshatri H (2013) PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinform 3(1):22. https://doi.org/10.1186/2043-9113-3-222043-9113-3-22 CrossRef

29.

Goswami CP, Nakshatri H (2014) PROGgeneV2: enhancements on the existing database. BMC Cancer 14:970. https://doi.org/10.1186/1471-2407-14-9701471-2407-14-970 CrossRefPubMedPubMedCentral

30.

Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, Laffaire J, de Reynies A, Beer DG, Timsit JF, Brambilla C, Brambilla E, Khochbin S (2013) Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 5(186):186ra166. https://doi.org/10.1126/scitranslmed.30057235/186/186ra66 CrossRef

31.

Choul-Li S, Leroy C, Leprivier G, Laitem C, Tulasne D, Aumercier M (2010) Caspase cleavage of Ets-1 p51 generates fragments with transcriptional dominant-negative function. Biochem J 426(2):229–241. https://doi.org/10.1042/BJ20090877BJ20090877 CrossRefPubMed

32.

Hui L, Liu B, Zhao L, Zhang S, Zhou B, Qiu X, Cui Z (2009) [High expression of twist is positively correlated with the differentiation of lung cancer. Zhongguo fei ai za zhi = Chin J Lung Cancer 12(4):294–299

33.

Saunders LR, McClay DR (2014) Sub-circuits of a gene regulatory network control a developmental epithelial-mesenchymal transition. Development 141(7):1503–1513. https://doi.org/10.1242/dev.101436dev.101436 CrossRefPubMedPubMedCentral

34.

Zhao Z, Rahman MA, Chen ZG, Shin DM (2017) Multiple biological functions of Twist1 in various cancers. Oncotarget 8(12):20380–20393. https://doi.org/10.18632/oncotarget.1460814608 PubMedPubMedCentralCrossRef

35.

Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N (2001) The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 194(1):43–50. https://doi.org/10.1002/path.844 CrossRefPubMed

36.

Grzegrzolka J, Biala M, Wojtyra P, Kobierzycki C, Olbromski M, Gomulkiewicz A, Piotrowska A, Rys J, Podhorska-Okolow M, Dziegiel P (2015) Expression of EMT markers SLUG and TWIST in breast cancer. Anticancer Res 35(7):3961–3968PubMed

37.

Jouppila-Matto A, Narkio-Makela M, Soini Y, Pukkila M, Sironen R, Tuhkanen H, Mannermaa A, Kosma VM (2011) Twist and snai1 expression in pharyngeal squamous cell carcinoma stroma is related to cancer progression. BMC Cancer 11:350. https://doi.org/10.1186/1471-2407-11-3501471-2407-11-350 CrossRefPubMedPubMedCentral

38.

Cheng Z, Teo G, Krueger S, Rock TM, Koh HW, Choi H, Vogel C (2016) Differential dynamics of the mammalian mRNA and protein expression response to misfolding stress. Mol Syst Biol 12(1):855. https://doi.org/10.15252/msb.20156423 CrossRefPubMedPubMedCentral

39.

Hong J, Zhou J, Fu J, He T, Qin J, Wang L, Liao L, Xu J (2011) Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Res 71(11):3980–3990. https://doi.org/10.1158/0008-5472.CAN-10-29140008-5472.CAN-10-2914 CrossRefPubMedPubMedCentral

40.

Xue G, Hemmings BA (2012) Phosphorylation of basic helix-loop-helix transcription factor Twist in development and disease. Biochem Soc Trans 40(1):90–93. https://doi.org/10.1042/BST20110678BST20110678 CrossRefPubMed

41.

Karlin S, Altschul SF (1990) Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proc Natl Acad Sci USA 87(6):2264–2268CrossRefPubMed

42.

Kopp JL, Wilder PJ, Desler M, Kim JH, Hou J, Nowling T, Rizzino A (2004) Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene. J Biol Chem 279(19):19407–19420. https://doi.org/10.1074/jbc.M314115200M314115200 CrossRefPubMed

43.

Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3):295–305. https://doi.org/10.1038/ncb1691ncb1691 CrossRefPubMed

44.

Gu Y, Lin S, Li JL, Nakagawa H, Chen Z, Jin B, Tian L, Ucar DA, Shen H, Lu J, Hochwald SN, Kaye FJ, Wu L (2012) Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 31(4):469–479. https://doi.org/10.1038/onc.2011.247onc2011247 CrossRefPubMed

45.

Hou X, Liu JE, Liu W, Liu CY, Liu ZY, Sun ZY (2011) A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation. Oncogene 30(26):2933–2942. https://doi.org/10.1038/onc.2011.19onc201119 CrossRefPubMed

46.

Kim DW, Chung HK, Park KC, Hwang JH, Jo YS, Chung J, Kalvakolanu DV, Resta N, Shong M (2007) Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol 21(12):3039–3049. https://doi.org/10.1210/me.2007-0269 CrossRefPubMed

47.

Liang X, Nan KJ, Li ZL, Xu QZ (2009) Overexpression of the LKB1 gene inhibits lung carcinoma cell proliferation partly through degradation of c-myc protein. Oncol Rep 21(4):925–931PubMed

48.

Moren A, Raja E, Heldin CH, Moustakas A (2011) Negative regulation of TGFbeta signaling by the kinase LKB1 and the scaffolding protein LIP1. J Biol Chem 286(1):341–353. https://doi.org/10.1074/jbc.M110.190660M110.190660 CrossRefPubMed

49.

van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP (2011) The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 30(20):2289–2303. https://doi.org/10.1038/onc.2010.630onc2010630 CrossRefPubMed

50.

Upadhyay S, Liu C, Chatterjee A, Hoque MO, Kim MS, Engles J, Westra W, Trink B, Ratovitski E, Sidransky D (2006) LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer. Cancer Res 66(16):7870–7879. https://doi.org/10.1158/0008-5472.CAN-05-2902 CrossRefPubMed

51.

Ratovitski EA (2010) LKB1/PEA3/DeltaNp63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure. Oxid Med Cell Longev 3(5):317–324CrossRefPubMedPubMedCentral

52.

Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM (2015) Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. Oncogenesis 4:e168. https://doi.org/10.1038/oncsis.2015.27oncsis201527 CrossRefPubMedPubMedCentral

53.

Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N, Vande Woude GF (2005) Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA 102(30):10528–10533. https://doi.org/10.1073/pnas.0504367102 CrossRefPubMed

54.

Kohrman AQ, Matus DQ (2017) Divide or conquer: cell cycle regulation of invasive behavior. Trends Cell Biol 27(1):12–25. https://doi.org/10.1016/j.tcb.2016.08.003 CrossRefPubMed

55.

Medwig TN, Matus DQ (2017) Breaking down barriers: the evolution of cell invasion. Curr Opin Genet Dev 47:33–40. https://doi.org/10.1016/j.gde.2017.08.003 CrossRefPubMed

56.

Dragoi D, Krattenmacher A, Mishra VK, Schmidt JM, Kloos UJ, Meixner LK, Hauck SM, Buggenthin F, Schwartz D, Marr C, Johnsen SA, Scheel CH (2016) Twist1 induces distinct cell states depending on TGFBR1-activation. Oncotarget 7(21):30396–30407. https://doi.org/10.18632/oncotarget.88788878 CrossRefPubMedPubMedCentral

57.

Kaur J, Tikoo K (2015) Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation. Oncogene 34(41):5216–5228. https://doi.org/10.1038/onc.2014.447onc2014447 CrossRefPubMedPubMedCentral

Title: ETS1 regulates Twist1 transcription in a KrasG12D/Lkb1−/− metastatic lung tumor model of non-small cell lung cancer
Authors: Guetchyn Millien
Yuxia Cao
Carl J. O’Hara
Jean-Bosco Tagne
Anne Hinds
Mary C. Williams
Maria I. Ramirez
Hasmeena Kathuria
Publication date: 01-03-2018
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 3/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9912-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey

Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines

Hemodynamic shear stress induces protective autophagy in HeLa cells through lipid raft-mediated mechanotransduction

11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France

Isolated pancreatic metastases from renal cell carcinoma: an outcome of a special metastatic pathway or of specific tumor cell selection?

Abstracts from the 11th International Symposium on Minimal Residual Disease, 3–5 May 2018, Montpellier, France

Keynote webinar | Spotlight on antibody–drug conjugates in cancer